CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists, hematologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lymphoma, chronic lymphocytic leukemia (CLL) and multiple myeloma (MM).
  
  LEARNING OBJECTIVES

  • Individualize the selection and sequencing of systemic therapy for patients with newly diagnosed and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), considering clinical presentation, biomarker profile and psychosocial status.
  • Evaluate available clinical trial data to formulate therapeutic recommendations for patients with newly diagnosed and R/R diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma and Hodgkin lymphoma.
  • Customize induction, consolidation and maintenance therapy approaches for multiple myeloma (MM) in the transplant and nontransplant settings, considering patient- and disease-related factors, such as cytogenetic profile.
  • Consider published research and other clinical factors in the best-practice selection, sequencing or combining of available therapeutic agents in the nonresearch care of patients with R/R MM.
  • Compare and contrast the mechanisms of action, efficacy and safety of approved and investigational immunotherapeutic approaches (eg, chimeric antigen receptor T-cell therapy, bispecific antibodies) for the treatment of non-Hodgkin lymphoma, CLL and MM to determine the current and potential utility of each in clinical practice.
  • Design and implement a plan of care to recognize and manage side effects and toxicities associated with existing and recently approved systemic therapies for CLL, lymphomas and MM to support quality of life and continuation of treatment.
  • Assess ongoing clinical trials evaluating novel investigational approaches for CLL, lymphomas and MM, and counsel appropriate patients about availability and participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  John N Allan, MD
  Associate Professor of Clinical Medicine
  Weill Cornell Medicine
  New York, New York
  
  Consulting Agreements: AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Epizyme Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, Pharmacyclics LLC, an AbbVie Company, TG Therapeutics Inc; Contracted Research: BeiGene Ltd, Celgene Corporation, Genentech, a member of the Roche Group, Janssen Biotech Inc, TG Therapeutics Inc; Nonpromotional Disease State Awareness Speaking: AbbVie Inc, BeiGene Ltd, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company.
  
  Shaji K Kumar, MD
  Mark and Judy Mullins Professor of Hematological Malignancies
  Consultant, Division of Hematology
  Professor of Medicine
  Mayo Clinic
  Rochester, Minnesota
  
  Advisory Committee: AbbVie Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc; Consulting Agreements (No Personal Payments): AbbVie Inc, Amgen Inc, Arcellx, AstraZeneca Pharmaceuticals LP, bluebird bio, Bristol Myers Squibb, Epizyme Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, K36 Therapeutics, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Monte Rosa Therapeutics, Sanofi, Secura Bio, Takeda Pharmaceuticals USA Inc, Trillium Therapeutics Inc; Consulting Agreements (with Personal Payments): Antengene, BeiGene Ltd, Oncopeptides; Data and Safety Monitoring Board/Committee: Bristol Myers Squibb, Janssen Biotech Inc; Research Funding for Clinical Trials to the Institution: AbbVie Inc, Allogene Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, CARsgen Therapeutics, Genentech, a member of the Roche Group, GSK, Janssen Biotech Inc, Novartis, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc.
  
  Ann S LaCasce, MD, MMSc
  Director, Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology
  Associate Professor of Medicine, Harvard Medical School
  Lymphoma Program
  Dana-Farber Cancer Institute
  Boston, Massachusetts
  
  Advisory Committee: Kite, A Gilead Company, Seagen Inc; Data and Safety Monitoring Board/Committee (Does Not Take Payment): Bristol Myers Squibb.
  
  Sagar Lonial, MD
  Chair and Professor
  Department of Hematology and Medical Oncology
  Chief Medical Officer
  Winship Cancer Institute
  Emory University
  Atlanta, Georgia
  
  Advisory Committee: AbbVie Inc, Amgen Inc, Bristol Myers Squibb, Celgene Corporation, Genentech, a member of the Roche Group, GlaxoSmithKline, Janssen Biotech Inc, Novartis, Pfizer Inc, Takeda Pharmaceuticals USA Inc; Board of Directors with Stock: TG Therapeutics Inc; Contracted Research: Bristol Myers Squibb, Janssen Biotech Inc, Novartis, Takeda Pharmaceuticals USA Inc.
  
  Loretta J Nastoupil, MD
  Associate Professor
  Section Chief, Indolent Lymphoma
  Department of Lymphoma/Myeloma
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Advisory Committee: Bristol Myers Squibb, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Janssen Biotech Inc, Kite, A Gilead Company, Merck, Novartis, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Consulting Agreements: AbbVie Inc, Incyte Corporation; Contracted Research: Bristol Myers Squibb, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Janssen Biotech Inc, Kite, A Gilead Company, Merck, Novartis, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Board/Committee: Genentech, a member of the Roche Group, Takeda Pharmaceuticals USA Inc
  
  Susan O’Brien, MD
  Professor, Division of Hematology/Oncology, School of Medicine
  UCI Chao Family Comprehensive Cancer Center
  Orange, California
  
  Consultant: AbbVie Inc, Alexion Pharmaceuticals, Amgen Inc, Aptose Bioscience Inc, Astellas, AstraZeneca Pharmaceuticals LP, Autolus Therapeutics, Bristol Myers Squibb, Celgene Corporation, Gilead Sciences Inc, GSK, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Juno Therapeutics, a Celgene Company, Lilly, MEI Pharma Inc, Merck, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, TG Therapeutics Inc, Vaniam Group, Verastem Inc, Vida Ventures LLC; Research Support: Acerta Pharma — A member of the AstraZeneca Group, BeiGene Ltd, Caribou Biosciences Inc, Gilead Sciences Inc, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Mustang Bio, Nurix Therapeutics Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Regeneron Pharmaceuticals Inc, TG Therapeutics Inc; Nonrelevant Financial Relationship: Alliance Pharma Inc, DynaMed, Nova Research Inc.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AbbVie Inc, Genentech, a member of the Roche Group, Genmab US Inc, Karyopharm Therapeutics, Lilly, Regeneron Pharmaceuticals Inc, Sanofi, and Seagen Inc.
  
  Release date: July 2023
  Expiration date: July 2024